Kürşat Bora ÇARMAN, Coşkun YARAR, Arzu EKICI, Sevgi YİMENİCİOĞLU, Ayten YAKUT

SUBAKUT SKLEROZAN PANENSEFALİTLİ HASTALARDA KLİNİK GİDİŞAT VE PROGNOZ

Amaç:Bu çalışmada Eskişehir Osmangazi Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı'nın Çocuk Nöroloji Ünitesinde yapılmıştır. 1998 ile 2011 yılları arasında Çocuk Nöroloji Bilim dalında SSPE tanısıyla izlenen 14 hasta retrospektif olarak incelenmiştir. Gereç:Hastaların son nörolojik durumu nörolojik defisit indeksi (NDI) ile tespit edilmiştir. Hastaların aşılama durumu, klinik bulguları göz bulguları ve beyin görüntüleme yöntemleri değerlendirilmiştir. Yöntemler: Hastalığı evrelerken Jabbour'un sınıflamasi kullanıldı. Hastaların BOS inclemesi yapıldı, BOS kızamık IgG ve IgM antikorları IFA yöntemi ile çalışıldı. Serum IgM kızamık antikoru, IgG kızamık antikoru ise ELİSA yöntemiyle çalışıldı.Bulgular:Toplam 14 hasta çalışmaya alındı. Hastaların ortalama yaşı 7.8 idi. Başvuru şikayetleri düşme atakları, konuşma bozukluğu, myoklini, konvulziyon, kognitif değişiklik, gece korkuları, tremor, enkoprezis, davranış değişikliği, görme kaybı, senkop, ensefalopati tablosuyla ile başvurmuşlar. Sonuç:Hastalar şikâyetleri başladıktan ortalama iki ay içerisinde hastaneye başvurmuştu. Şikayet başlangıcı ile tanı koyma arasında geçen süre 2 -4 ay arasında idi. Hastalarımızdan 3 tanesine akut fulminan bir seyir gelişti, biri hastanede sepsis nedeniyle diğer 2'si taburculuktan sırasıyla 1.5, 2 ay sonra kaydedildi.

Clinical Follow Up and Prognosis of Patients With Subacute Sclerosing Panencepahlitis

Purpose:In this study, we retrospectivley evalutaed fourten patients admitted to Eskişehir Osmangazi University pedıatric neurology departmen between the years 1998-2011. Material: Patient's last neurologic state is examined by neurologic deficiıt index (NDI). Vaccination state, clinical findings, visual findings, cerebral imaging findings are evaluated. Methods:Jabbour classification is used for staging of the disease. Patients' cerebrospinal findings are recorded, CSF IgM andI g G anticore titers are studied with IFA method. Serum IgM andI g G anticore titers are studied with ELISA method. Findings:Fourteen patients are included in the study. Patients median age was 7.8. Presenting symptoms were drop attacks, speech disturbances, myoclonus, convulsions, cognitive dysfunction, night terrors, tremor, encopresis, changes in behaviour, vision loss, syncope, encepaholpathy. Result:Patients had admitted to the hospital within the two months of onset of the symptom. The duration between the beginning of the complaint and diagnosis was 2-4 months. Acute fulminating progress was seen in three patients, one patients died because of sepsis, the other two were died at follow-up 1.5 and two months after discharge from the hospital retrospectively.

PDF

___

Dyken P, DuRant R, Shmunes P. Subacute sclerosing panencephalitis surveillance- United States. MMWR 1982; (43):585-88.
Onal AE, Gurses C, Direskeneli GS, Yilmaz G, Demirbilek V, Yentur SP et.al. Subacute sclerosing panencephalitis surveillance study in Istanbul. Brain Dev. 2006;28(3):183-89.
Bellini WJ, Rota JS, Lowe LE, Katz RS, Dyken PR, Zaki SR, et al. Subacute sclerosing panencephalitis: more cases of this disease are prevented by measles immunization than was previously recognized. J Infect Dis. 2005;192(10):1686-93.
Dyken PR. Subacute sclerosing panencephalitis. Current status. Neurol Clin. 1985;3(1):179-96.
Dyken PR, Swift A, DuRant RH. Long -term follow-up of patients with subacute sclerosing panencephalitis treated with inosiplex. Ann Neurol. 1982; 11(4): 359-64.
Garg RK. Subacute sclerosing panencephalitis. Postgrad Med J.2002; 78(916):63-70
Jabbour JT, Garcia JH, Lemmi H, et al. Subacute sclerosing panencephalitis. A multidisciplinary study of eight cases. JAMA. 1969; 207(12): 2248-54.
Garg RK. Subacute sclerosing panencephalitis. J Neurol. ;255(12):1861-71.
Campbell C, Levin S, Humphreys P, et al. Subacute sclerosing panencephalitis: results of the Canadian paediatric surveillance program and review of the literature. BMC Pediatrics. 2005; 5(1): 5-47.
World Health Organization. Global Advisory Committee on Vaccine Safety, December 2005. Wkly Epidemiol Rec. :15-19.
Campbell H, Andrews N, Brown KE, Miller E. Review of the effect of measles vaccination on the epidemiology of SSPE. Int J Epidemiol. 2007;36: 1334-48.
Reuter D, Schneider-Schaulies J. Measles virus infection of the CNS: human disease, animal models, and approaches to therapy. Med Microbiol Immunol. 2010;199(3):261-71.
Yilmaz D, Aydin OF, Senbil N, Yuksel D. Subacute sclerosing panencephalitis: is there something different in the younger children? Brain Dev. 2006; 28(10): 649-52.
Manayani DJ, Abraham M, Gnanamuthu C, Solomon T, Alexander M, Sridharan G. SSPE - the continuing challenge: a study based on serological evidence from a teritary care centre in India. Indian J Med Microbiol. 2002;20(1):16-8.
Herguner MO, Altunbasak S, Baytok V. Patients w ith acute, fulminant form of SSPE. Turk J Pediatr. 2007; 49(2): -5.
Akram M, Naz F, Malik A, Hamid H. Clinical profile of subacute sclerosing panencephalitis. J Coll Physicians Surg Pak. 2008; 18(8): 485-8.
Kissani N, Ouazzani R, Belai di H, Ouahabi H, Chkili T. Epileptic seizures and e pilepsy in subacute sclerosing panencephalitis (report of 30 cases). Neurophysiol Clin. ; 31(6): 398 -405.
Ozturk A, Gurses C, Baykan B, Gokyigit A, Eraksoy M Subacute sclerosing panencephalitis: clinical and magnetic resonance imaging evaluation of 36 patients. J Child Neurol ;17(1):25- 29.
Prashanth LK, Taly AB, Sinha S, Ravi V. Subacute sclerosing panencephalitis (SSPE): an insight into the diagnostic errors from a tertiary care university hospital. J Child Neurol. 2007; 22(6):683 - 88.
Yuksel D, Sonmez PA, Yilmaz D, Senbil N, Gurer Y.Ocular findings in subacute sclerosing panencephalitis. Ocul Immunol Inflamm. 2011;19(2):135-8.
Serdaroğlu A, Gücüyener K, Dursun I, Aydin K, Okuyaz C, Subaşi M, Or M, Ozkan B. Macular retinitis as a first sign of subacute sclerosing panencephalitis: the importance of early diagnosis. Ocul Immunol Inflamm. 2005;13(5):405-10.
Cochereau-Massin I, Gaudric A, Reinert P, Lehoang P, Rousselie F, Coscas G. Changes in the fundus in subacute sclerosing panencephalitis. Apropos of 23 cases. J Fr Ophtalmol. 1992;15(4):255-61.
R Tandon, S Khanna, MC Sharma, S Seshadri, V Menon. Subacute sclerosing panencephalitis presenting as optic neuritis. Indian J Ophthalmol. 1999;47(4):250-52.
Erturk O, Karslıgil B, Cokar O, Yapici Z, Demirbilek V, Gurses C, Yalcinkaya C, Gokyigit A, Direskeneli GS, Yentur S, Onal E, Yilmaz G, Dervent A. Challenges in diagnosing SSPE. Childs Nerv Syst. 2011;27(12):2041-44.
Salehi HR, Delgado E, Wolf SM, McGoldrick PE, Moshé SL. Subacute sclerosing panencephalitis with atypical features. Pediatr Neurol. 2005 ;33(4):280-82.
Mgone CS, Mgone JM, Takasu T, Miki K, Kawanishi R, Asuo PG, Kono J, Komase K, Alpers MP. Clinical presentation of subacute sclerosing panencephalitis in Papua New Guinea. Trop Med Int Health. 2003;8(3):219-27.
Markand OM, Pasnzi JG. The electroencephalogram in subacute sclerosing panencephalitis. Arch Neurol. 1975; (11): 719-26.
Brismar J, Gascon GG, Von Steyern KV et al : Subacute sclerosing panencephalitis: Evaluation with CT and MR. AJNR. 1996; 17(4) : 761-22
Öz B. Subacute sclerosing panencephalitis: Case report and literature review. Cerrahpaşa J Med. 2000; 31 (2): 107
Trivedi R, Gupta RK, Agarawal A, Hasan KM, Gupta A, Prasad KN, Bayu G, Rathore D, Rathore RK, Narayana PA. Assessment of white matter damage in subacute sclerosing panencephalitis using quantitative diffusion tensor MR imaging. AJNR Am J Neuroradiol. 2006;27(8):1712-16.
Chang TW, Heel RC: Ribavirin and inosiplex: a review of their present status in viral diseases. Drugs. 1981; (2):111-28.
Anlar B: Subacute sclerosing panencephalitis: Diagnosis and drug treatment options. CNS Drugs. 1997; 7(2):111
Anlar B, Yalaz K, Kose G, Saygi S. ß-Interferon plus inosiplex in the treatment of subacute sclerosing panencephalitis. J Child Neurol.1998; 13(11):557-59.
Tomoda A, Nomura K, Shiraishi S, Hamada A, Ohmura T, Hosoya M, et al. Trial of intraventricular ribavirin therapy for subacute sclerosing panencephalitis in Japan. Brain Dev. ;25(7):514-17.
Hosoya M, Mori S, Tomoda A, Mori K, Sawaishi Y, Kimura H, Shigeta S, Suzuki H. Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis. Antimicrob Agents Chemother. 2004; 48(12):4631-635.
Gascon GG; International Consortium on Subacute Sclerosing Panencephalitis Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): international multicenter study. J Child Neurol. ;18(12):819-27.
Demir E, Aksoy A, Anlar B, Sönmez FM (2007) Atypical presentations of SSPE: a clinical study in four cases. Turk J Pediatr. 49(3):295-300
Marjanovi c BD, Stojanov LM, Z amurov ic DR , Pasic SS, Kravljanac R M, Djordjevi MS. Fulminant subacute sclerosing panencephalitis: two cases with atypical presentation. Pediatr Neurol.2003; 29(1):63-65